Development of rash indicates positive outcome in erlotinib-treated patients
This article has no abstract so we have provided the first paragraph of the full text.
Patients treated with EGFR inhibitors frequently develop a rash. Previous studies have suggested a positive association between outcome and rash development. A study by Wacker et al. has examined the correlation between the clinical efficacy of EGFR inhibitors and the development of rash using data from two phase III studies.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.